These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Posttransplant lymphoproliferative disease following liver transplantation. Kamdar KY; Rooney CM; Heslop HE Curr Opin Organ Transplant; 2011 Jun; 16(3):274-80. PubMed ID: 21467936 [TBL] [Abstract][Full Text] [Related]
44. Hodgkin lymphoma-like posttransplant lymphoproliferative disorder (HL-like PTLD) simulates monomorphic B-cell PTLD both clinically and pathologically. Pitman SD; Huang Q; Zuppan CW; Rowsell EH; Cao JD; Berdeja JG; Weiss LM; Wang J Am J Surg Pathol; 2006 Apr; 30(4):470-6. PubMed ID: 16625093 [TBL] [Abstract][Full Text] [Related]
45. Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Allen UD; Preiksaitis JK; Clin Transplant; 2019 Sep; 33(9):e13652. PubMed ID: 31230381 [TBL] [Abstract][Full Text] [Related]
46. Post-transplant lymphoproliferative disease in pediatric solid organ transplant recipients. Wistinghausen B; Gross TG; Bollard C Pediatr Hematol Oncol; 2013 Sep; 30(6):520-31. PubMed ID: 23802715 [TBL] [Abstract][Full Text] [Related]
47. Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab. Svoboda J; Kotloff R; Tsai DE Transpl Int; 2006 Apr; 19(4):259-69. PubMed ID: 16573540 [TBL] [Abstract][Full Text] [Related]
48. Post Transplant Lymphoproliferative Disorder risk factors in children: Analysis of a 23-year single-institutional experience. Bosse RC; Franke AJ; Paul Skelton W; Woody LE; Bishnoi R; Wang Y; Bhaduri-McIntosh S; Rajderkar D; Shih R; Dang NH; Slayton WB Pediatr Transplant; 2020 Aug; 24(5):e13747. PubMed ID: 32497335 [TBL] [Abstract][Full Text] [Related]
53. Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLD registry. Zimmermann H; Nitsche M; Pott C; Reinke P; Babel N; Hermann RM; Hauser IA; Hahn D; Ritgen M; Pietschmann C; Klapper W; Anagnostopoulos I; Trappe RU; Ann Hematol; 2021 Aug; 100(8):2043-2050. PubMed ID: 33973053 [TBL] [Abstract][Full Text] [Related]
54. Detection of Epstein-Barr virus DNA in sera from transplant recipients with lymphoproliferative disorders. Limaye AP; Huang ML; Atienza EE; Ferrenberg JM; Corey L J Clin Microbiol; 1999 Apr; 37(4):1113-6. PubMed ID: 10074534 [TBL] [Abstract][Full Text] [Related]
55. Management of paediatric monomorphic post-transplant lymphoproliferative disorders with low-intensity treatment: A multicentre international experience. Guerra-García P; Bomken S; Ling R; Lazareva A; Gupte G; Amrolia P; Andrés M; Diez-Sebastián J; Taj MM Pediatr Blood Cancer; 2024 Aug; 71(8):e31053. PubMed ID: 38757407 [TBL] [Abstract][Full Text] [Related]
56. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression. Newell KA; Alonso EM; Whitington PF; Bruce DS; Millis JM; Piper JB; Woodle ES; Kelly SM; Koeppen H; Hart J; Rubin CM; Thistlethwaite JR Transplantation; 1996 Aug; 62(3):370-5. PubMed ID: 8779685 [TBL] [Abstract][Full Text] [Related]
57. Risk factors for adenotonsillar hypertrophy in children following solid organ transplantation. Shapiro NL; Strocker AM; Bhattacharyya N Int J Pediatr Otorhinolaryngol; 2003 Feb; 67(2):151-5. PubMed ID: 12623151 [TBL] [Abstract][Full Text] [Related]